Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; Association with pro-inflammatory cytokines

European Journal of Haematology

Volumn 76, Issue 3, 2006, Pages 265-268

  Min, Chang Ki ^a,b   Lee, Seok ^a,b   Kim, Yoo Jin ^a,b   Eom, Ki Seong ^a,b   Lee, Jong Wook ^a,b   Min, Woo Sung ^a,b   Kim, Chun Choo ^a,b   Cho, Chul Soo ^a,b   Park, Gyeongsin ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Bortezomib; IL 6; Leucolcastic vasculitis; Multiple myeloma; TNF

Indexed keywords

BORTEZOMIB; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BACK; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CONCENTRATION (PARAMETERS); DOSE RESPONSE; ENTEROPATHY; FACE; FEVER; HUMAN; HUMAN TISSUE; LEUCOCLASTIC VASCULITIS; LIMB; MALE; MYELOMA; PRIORITY JOURNAL; PRURITUS; PURPURIC RASH; RASH; SERUM; SKIN DISEASE; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; TRUNK; VASCULITIS;

BORONIC ACIDS; CYTOKINES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SKIN; VASCULITIS, ALLERGIC CUTANEOUS;

EID: 33645071066     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.0902-4441.2005.t01-1-EJH2437.x     Document Type: Article

References (15)

1. K yle RA R ajkumar SV. Multiple myeloma N Engl J Med 2004 351 1860 1873
2. R ichardson PG B arlogie B B erenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 2003 348 2609 2617
3. J agannath S B arlogie B B erenson J et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 2004 127 165 172
4. R ichardson PG S onneveld P S chuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 2005 352 2487 2498
5. C ollins WJ B endig DW T aylor WF. Pulmonary vasculitis complicating childhood ulcerative colitis Gastroenterology 1979 77 1091 1093
6. S chultz DR A rnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein and fibrinogen Sem Arthritis Rheum 1990 20 129 147
7. C astell JV G omez -L echon MJ D avid M et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6 Hepatology 1990 12 1179 1186
8. R ajkumar SV R ichardson PG H ideshima T A nderson KC. Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 2005 23 630 639
9. E lliott PJ Z ollner TM B oehncke WF. Proteasome inhibition: a new anti-inflammatory strategy J Mol Med 2003 81 235 245
10. L awrence T G ilroy DW C olville -N ash PR W illoughby DA. Possible new role for NF-κB in the resolution of inflammation Nat Med 2001 7 1291 1297
11. S un K W elniak LA P anoskaltsis -M ortari A et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib Proc Natl Acad Sci USA 2004 101 8120 8125
12. S un K W ilkins DE A nver MR S ayers TJ P anoskaltsis -M ortari A B lazar BR W elniak LA M urphy WJ. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity Blood 2005 106 3293 3299
13. M itsiades N M itsiades CS P oulaki V et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proc Natl Acad Sci USA 2002 99 14374 14379
14. S tasi R B runetti M P arma A D i G iulio C T erzoli E P agano A. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma Cancer 1998 82 1860 1866
15. H ahn T W ingard JR A nderson KC B ensinger WI B erenson JR B rozeit G C arver JR K yle RA M c C arthy PL. Jr The role of cytotoxic therapy withhematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review Biol Blood Marrow Transplant 2003 9 4 37